Innate Pharma SA, of Marseille, France, opened the phase I/II trial of IPH2201, a first-in-class NKG2A checkpoint inhibitor, tested in combination with ibrutinib (Imbruvica, Pharmacyclics Inc./Johnson & Johnson) in patients with relapsed or refractory chronic lymphocytic leukemia.